Biosergen

Norway
Trondheim, Trøndelag, Norway, 7034

Company profile

Biosergen company profile

Biosergen develops variants of nystatin with improved properties. Its pipeline products include S44HP, an antibiotic that is more potent than nystatin against several fungal pathogens; and nystatin analogues produced through manipulation of the nystatin biosynthetic genes.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2004-01-01, Year

Headquarters

Postal code
7034
Country code
NO
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
3
Total equity funding
$4.1M
Last funding
Post IPO Equity / $4.1M / 2024-11-18
Last equity funding
Post IPO Equity / $4.1M
Investors
2
Articles
29
Exited on
2021-07-16

Founders and investors

Investors

Rosetta CapitalSINTEF Venture AS